SEARCH
Enter your search term below:
Close
Enter your search term below:
WORLD LEADING BUSINESS SUPPORT
iQur is concentrating its therapeutic research and development on a vaccine platform based on exploiting the immune stimulant properties of Hepatitis B core. iQurÕs patented Tandem Core Technology (TCT) relies on the linkage of two HBV core molecules to form a stable backbone that combines to form virus like particles. Insertion of target antigens into the TCT produces a vaccine that combines the immune alert signal provided by the HBV core with targeting of the immune response to the inserted vaccine antigen. This technology can be used to generate immune responses against infectious pathogens including viruses, bacteria and parasites such and malaria, agents used in biodefence, anima pathogens and cancer associated antigens.
Get all the fresh insights first! Stay up-to-date with all the
latest investment news, blogs and all things SETsquared.
Close
There are 10 award categories up for grabs at this year’s @UKBAngels Angel Investment Awards, celebrating early-sta… twitter.com/i/web/status/13830…
RT @dbahub: Are you raising investment in the health & wellbeing sector? Investing in Health Innovation: Data, Devices and Diag… https://t.co/7cCipPCZUH
Our #InnovationWorkout sees change as a positive force and not the enemy. Change can unlock new value and our fully… twitter.com/i/web/status/13830…
Our Q&A with a range of experts in investment and sustainable innovation tackles some important questions:
How ca… twitter.com/i/web/status/13829…
The Good Grant Guide Workshop
26 April, 10am-12pm
This two-hour interactive virtual webinar from @anchored_in… twitter.com/i/web/status/13826…
SETsquared is a partnership between